"Administration, Oral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The giving of drugs, chemicals, or other substances by mouth.
| Descriptor ID |
D000284
|
| MeSH Number(s) |
E02.319.267.100
|
| Concept/Terms |
Administration, Oral- Administration, Oral
- Drug Administration, Oral
- Oral Drug Administration
- Oral Administration
- Administrations, Oral
- Oral Administrations
- Administration, Oral Drug
- Administrations, Oral Drug
- Drug Administrations, Oral
- Oral Drug Administrations
|
Below are MeSH descriptors whose meaning is more general than "Administration, Oral".
Below are MeSH descriptors whose meaning is more specific than "Administration, Oral".
This graph shows the total number of publications written about "Administration, Oral" by people in this website by year, and whether "Administration, Oral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 9 | 9 |
| 1997 | 0 | 11 | 11 |
| 1998 | 0 | 13 | 13 |
| 1999 | 0 | 13 | 13 |
| 2000 | 0 | 7 | 7 |
| 2001 | 0 | 17 | 17 |
| 2002 | 0 | 21 | 21 |
| 2003 | 0 | 18 | 18 |
| 2004 | 0 | 15 | 15 |
| 2005 | 0 | 15 | 15 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 17 | 17 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 17 | 17 |
| 2010 | 0 | 14 | 14 |
| 2011 | 0 | 16 | 16 |
| 2012 | 0 | 10 | 10 |
| 2013 | 0 | 17 | 17 |
| 2014 | 0 | 14 | 14 |
| 2015 | 0 | 16 | 16 |
| 2016 | 0 | 21 | 21 |
| 2017 | 0 | 18 | 18 |
| 2018 | 0 | 26 | 26 |
| 2019 | 0 | 19 | 19 |
| 2020 | 0 | 19 | 19 |
| 2021 | 0 | 14 | 14 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 6 | 6 |
| 2024 | 0 | 9 | 9 |
| 2025 | 0 | 12 | 12 |
| 2026 | 0 | 8 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Administration, Oral" by people in Profiles.
-
Efficacy and safety of oral type II topoisomerase inhibitors versus ceftriaxone-based regimens for the treatment of gonorrhoea: A systematic review and meta-analysis of randomised controlled trials. J Infect Chemother. 2026 Sep; 32(9):103038.
-
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia. N Engl J Med. 2026 Jun 04; 394(21):2107-2116.
-
A Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine Sodium for the Treatment of Hypothyroidism in Adults. Thyroid. 2026 08; 36(8):853-861.
-
The safety and tolerability of oral TDF/FTC as pre-exposure prophylaxis among men who have sex with men in China: a prospective cohort study. BMC Infect Dis. 2026 May 21; 26(1).
-
A review of the State-of-the-Art: progress in ultrasonic and acoustic techniques for quality assessment in the development and manufacturing of oral solid dosage forms - Part II: Applications and emerging directions. Int J Pharm. 2026 Jun 05; 698:126925.
-
Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2026 04 21; 69(1):e51.
-
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Ann Rheum Dis. 2026 Sep; 85(9):1879-1889.
-
D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice. Nutrients. 2026 Feb 23; 18(4).
-
Potential alternative dosage strategies for patent-protected oral cancer drugs. Eur J Cancer. 2025 Nov 17; 230:116067.
-
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial. CNS Drugs. 2026 01; 40(1):99-109.